Waheed Dur-E-Nayab, Olivier Catherine Weil, Riethmuller Didier, Franco Eduardo L, Prétet Jean Luc, Baay Marc, Munoz Nubia, Vorsters Alex
Centre for Evaluation of Vaccination, Vaccine and Infectious Disease Institute University of Antwerp, Antwerp, Belgium.
Retired, Neuilly-Sur-Seine, France.
BMC Proc. 2023 Aug 3;17(Suppl 11):18. doi: 10.1186/s12919-023-00271-0.
Misinformation regarding HPV vaccine safety and benefits has resulted in low coverage within the eligible French population. HPV vaccination is safe and efficacious in preventing HPV infections in adolescents. However, reaching optimal coverage in countries such as France is challenging due to misinformation, among other factors. Moreover, disparities exist in cervical cancer screening programs. To support the government health promotion policy aimed at improving prevention and control of HPV-related cancers in France, the Human Papillomavirus Prevention and Control Board (HPV-PCB), in collaboration with local experts, held a meeting in Annecy, France (December 2021).HPV-PCB is an independent, multidisciplinary board of international experts that disseminates relevant information on HPV to a broad array of stakeholders and provides guidance on strategic, technical and policy issues in the implementation of HPV control programs.After a one-and-a-half-day meeting, participants concluded that multi-pronged strategies are required to expand vaccination coverage and screening. Vaccine acceptance could be improved by: 1) strenghtening existing trust in clinicians by continuous training of current and upcoming/pre-service healthcare professionals (HCPs), 2) improving health literacy among adolescents and the public through school and social media platforms, and 3) providing full reimbursement of the gender-neutral HPV vaccine, as a strong signal that this vaccination is essential.The discussions on HPV infections control focused on the need to: 1) encourage HCPs to facilitate patient data collection to support performance assessment of the national cervical cancer screening program, 2) advance the transition from cytology to HPV-based screening, 3) improve cancer prevention training and awareness for all HCPs involved in screening, including midwives, 4) identifying patient barriers to invitation acceptance, and 5) promoting urine or vaginal self-sampling screening techniques to improve acceptability, while establishing appropriate follow-up strategies for HPV-positive women. This report covers some critical findings, key challenges, and future steps to improve the status of HPV prevention and control measures in the country.
关于人乳头瘤病毒(HPV)疫苗安全性和益处的错误信息导致符合条件的法国人群疫苗接种覆盖率较低。HPV疫苗在预防青少年HPV感染方面是安全有效的。然而,由于错误信息等因素,在法国等国家实现最佳覆盖率具有挑战性。此外,宫颈癌筛查项目也存在差异。为支持法国政府旨在加强HPV相关癌症预防和控制的健康促进政策,人乳头瘤病毒预防与控制委员会(HPV-PCB)与当地专家合作,于2021年12月在法国安纳西召开了一次会议。HPV-PCB是一个由国际专家组成的独立多学科委员会,向广泛的利益相关者传播有关HPV的相关信息,并就HPV控制项目实施中的战略、技术和政策问题提供指导。经过一天半的会议,与会者得出结论,需要采取多管齐下的策略来扩大疫苗接种覆盖率和筛查范围。可以通过以下方式提高疫苗接受度:1)通过对在职和即将入职/岗前医疗保健专业人员(HCPs)进行持续培训,加强对临床医生现有的信任;2)通过学校和社交媒体平台提高青少年和公众的健康素养;3)全额报销不分性别的HPV疫苗费用,以此强烈表明这种疫苗至关重要。关于HPV感染控制的讨论集中在以下必要性上:1)鼓励HCPs协助收集患者数据,以支持国家宫颈癌筛查项目的绩效评估;2)推动从细胞学筛查向基于HPV的筛查转变;3)提高所有参与筛查的HCPs(包括助产士)的癌症预防培训和意识;4)确定患者接受邀请的障碍;5)推广尿液或阴道自我采样筛查技术以提高接受度,同时为HPV阳性女性制定适当的后续策略。本报告涵盖了一些关键发现、主要挑战以及改善该国HPV预防和控制措施现状的未来步骤。